PATENTSCOPE will be unavailable a few hours for maintenance reason on Monday 03.02.2020 at 10:00 AM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2010081112) PREVENTION AND/OR TREATMENT OF MULTIPLE ORGAN DYSFUNCTION SYNDROME WITH INTERLEUKIN-22
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

What is claimed is:

1. A method of prevention or treatment of multiple organ dysfunction syndromes in a subject comprising administering a pharmaceutically effective amount of IL-22.

2. The method of claim 1 wherein said IL-22 increases serum total protein in said subject suffering multiple organ dysfunction syndromes.

3. The method of claim 1 wherein said IL-22 increases serum albumin in said subject suffering multiple organ dysfunction syndromes.

4. The method of claim 1 wherein said IL-22 is mammal IL-22.

5. The method of claim 1 wherein said IL-22 is recombinant mammal IL-22.

6. The method of claim 1 wherein said pharmaceutically effective amount of IL-22 ranges from 100 to 1000 micrograms per kilogram of said subject per day.

7. A method of prevention or treatment of systemic inflammatory response syndrome in a subject comprising administering a pharmaceutically effective amount of IL-22.

8. The method of claim 7 wherein said IL-22 increases the survival rate of said subject.

9. The method of claim 7 wherein said IL-22 is mammal IL-22.

10. The method of claim 7 wherein said IL-22 is recombinant mammal IL-22.

11. The method of claim 7 wherein said pharmaceutically effective amount of IL-22 ranges from 100 to 500 micrograms per kilogram of said subject.

12. A method of prevention or treatment of liver failure in a subject comprising administering a pharmaceutically effective amount of IL-22.

13. The method of claim 12 wherein said IL-22 lowers serum AST and ALT levels in said subject.

14. The method of claim 12 wherein said IL-22 is mammal IL-22.

15. The method of claim 12 wherein said IL-22 is recombinant mammal IL-22.

16. The method of claim 12 wherein said pharmaceutically effective amount of IL-22 ranges from 100 to 300 micrograms per kilogram of said subject.